BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock
BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock...
Yahoo! Finance: News
More News
Boston Scientific (BSX) Stock Moves -1.27%: What You Should Know
Boston Scientific (BSX) concluded the recent trading session at $48.34, signifying a -1.27% move from its prior day's close.
Zacks
Boston Scientific (BSX) Rises Higher Than Market: Key Facts
Boston Scientific (BSX) concluded the recent trading session at $48.85, signifying a +2.43% move from its prior day's close.
Zacks
Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet
According to the average brokerage recommendation (ABR), one should invest in Boston Scientific (BSX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Zacks
Can ISRG's Digital Roadmap Unlock the Next Phase of Robotic Surgery?
Intuitive Surgical is building an AI-driven surgical ecosystem, using da Vinci 5 data and connected workflows to deepen its robotic surgery moat.
Zacks
Why Did BSX, LOW, CAG Fall To 52-Week Lows Today?
Boston Scientific was down about 0.7% at close, while Lowe's Companies ended the session 3% lower, and Conagra Brands fell by about 1.3%.
Stocktwits
Wolfe Research Downgrades Boston Scientific Corporation (BSX) To Peer Perform
Wolfe Research Downgrades Boston Scientific Corporation (BSX) To Peer Perform...
Yahoo! Finance: News
TFX Stock Setup: Valuation, Leverage, and a Neutral Zacks Rank
Teleflex's portfolio reset is pressuring results, but a cheaper valuation and divestiture proceeds could reshape its outlook over the next 6-12 months.
Zacks
Why Did BSX, LI, ROL Stocks Fall To 52-Week Lows On Friday?
Analyst downgrades, weak outlooks, and management changes added pressure.
Stocktwits
Teleflex Divestitures: What Investors Should Watch in 2026
TFX targets $2.03B in divestiture proceeds; FTC review, tariffs and remediation costs put 2026 timing, margins and leverage in play.